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Abstract
Squamous cell carcinoma (SCC) of the head and neck region is the sixth most frequent malignancy with high mortality rate. Due
to its poor prognosis it is considered a growing public health problem worldwide inspite of existing treatment modalities. Thus,
early diagnosis of new diseases and recurrences is emerging on one hand, but on the other hand troublesome in the lack of reliable
tumor markers in this field. The rapid development of proteomics has opened new perspectives in tumor marker discovery.
Liquid chromatography/mass spectrometry (LC/MS) as the gold standard in proteomics enables the semi-quantitative analysis of
proteins within various tissues. Abundance differences between tumor and normal tissue also can be interpreted as tumor specific
changes. The aim of this study was to identify potential tumor markers of laryngeal/hypopharyngeal SCC by revealing abundance
changes between cancerous and the surrounding phenotypically healthy tissue. After separating the phenotypically cancerous and
healthy parts of formalin-fixed paraffin-embedded tissues, each sample underwent protein recovery process and tryptic digestion
for label-free semi-quantitative LC/MS analysis. Eight proteins showed significantly higher abundance in tumor including
tenascin, transmembrane emp24 domain-containing protein 2, cytoplasmic dynein light chain 1, coactosin-like protein, small
proline-rich protein 2D, nucleolin, U5 small nuclear RNP 200-kDa helicase and fatty aldehyde dehydrogenase. Desmoglein-1
and keratin type I cytoskeletal 9 were down-regulated in tumor. Using Ingenuity Pathway Analysis we mapped the signaling
pathways these proteins play role in regarding other tumors. Based on these findings these proteins may serve as promising
biomarkers in the fight against laryngeal/hypopharyngeal SCCs.
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Introduction
Head neck squamous cell carcinoma (HNSCC) is the 6th most
frequent malignancy [1] related with nicotine and alcohol
abuse [2]. Its incidence is three-fold higher in males. Due to
the aspecific symptoms most HNSCCs are diagnosed with
advanced stage indicating growing public health problem
worldwide The low 5-year overall survival rate has not
changed significantly in the past decade despite surgical and
oncological innovations [3].
Thus, early diagnosis and better understanding of tumor be-
havior is essential. HNSCCs probably produce several proteins
that could be utilized as tumormarkers. In possession of reliable
markers not only screening and early recognition, but early
detection of recurrence could be achieved. In addition, some
markers may serve as promising targets for biological therapies.
Due to rapid proteomics development, a newway has opened
in biomarker discovery. Beside evaluating epigenetic modifica-
tions, on-tissue protein distribution investigation and protein im-
aging also became available [4]. As potential biomarkers are
mostly unknown, labeling can not be used in discovery contrary
to label-free semiquantitative methods. Without labeling, inten-
sity of distinct peptides appropriately follows their abundance
changes. Nevertheless, label-free methods are more cost-effi-
cient. LC/MS possesses these advantages. Its high throughput
feature also makes it powerful in protein discovery. Initially,
proteomic analysis of solid tumors with mass spectrometry
(MS) was available only on fresh frozen samples. Therefore,
growing demand for analysis of formalin fixed paraffin embed-
ded (FFPE) tissue samples appeared. Development of tissue
preparation protocols enabled the elimination of formaldehyde
induced protein cross-linkings disturbing MS. Overcoming this
formerly limiting factor, an invaluable perspective has opened in
retrograd analysis due to broad histological sample archives used
in daily clinical practice.
The present study aims to investigate protein abundance dif-
ferences between laryngeal/hypopharyngeal squamous cell car-
cinoma (LHSCC) and phenotypically normal tissue on FFPE
samples to identify potential tumor markers. Furthermore, based
on the literature and Ingenuity Pathway Analysis (IPA), we aim
to map the pathways these proteins take part in other malignant
tumors in order to evaluate them as possible candidates for target
therapy of HNSCCs in the future.
Material and Methods
Patients
Sixteen consenting patients (16 males, median age 61 yrs.,
range from 45 yrs. to 79 yrs) diagnosed with LHSCC were
enrolled. Heavy smoking and regular alcohol consumption
were reported in all cases. All tumors were advanced primary
cases (stage III-IV.A). Exclusion criteria included non-SCC
histology, HPV positivity, previous oncological treatment and
recurrence or second primary tumor.
Method
Clinical examination included biopsy from all tumors for di-
agnosis prior to treatment. Biopsy samples were fixed in for-
malin followed by paraffin-embedding, sectioning and
hematoxylin-eosin (HE) staining. Histological examination
confirmed HNSCC in all cases.
For research purposes, all corresponding paraffin-embedded
tissue blocks were retrieved and further sections (15 μm thick-
ness) weremade from original blocks and placed to conventional
histological plate without staining. In addition, another HE
stained section (7 μm thickness) was made from blocks with
one obvious malignant field marked by the pathologist on the
contralateral side of the plate. Based on this marking, identical
part of each plate containing unstained paraffin-fixed section was
drawn around in the sameway. Deparaffinization was performed
by washing the unstained slides with xylol, ethanol 90% (m/m),
ethanol 70% (m/m), ethanol 50% (m/m) and 50 mM ammoni-
um-bicarbonate, respectively. Antigen retrieval was performed
with 100 mM Tris-HCl buffer (97 °C, 30 min). According to
the marked field lining histologically obvious malignant part, the
tissuewasmicrodissectedwith a fine needle and collected to 2ml
Eppendorf tube containing SDS lysis buffer. Tumor adjacent
normal tissue was also microdissected and each sample was
incubated in the lysis buffer (97 °C, 30min). After centrifugation
ice cold absolute ethanol was added to the supernatant with 9
volume surplus. Samples were kept at 4 °C overnight for protein
precipitation. The pellet was washed twice with absolute ethanol,
proteins were solubilized with 8 M urea. Reduction and alkyl-
ation were followed by overnight trypsin digestion. The resulting
tryptic peptides were cleaned using Pierce C18 spin columns
(Thermo Fisher Scientific, Waltham, MA). The MS used for
analysis was a Bruker mAXIS II ETD Q-TOF (Bruker
Daltonics, Bremen, Germany) coupled to an Ultimate 3000
nanoRSLC system (Dionex, Sunnyvale, CA, USA). Samples
were injected on an Acclaim PepMap100 C-18 trap column
(100 μm×20 mm, Thermo Scientific, Sunnyvale, CA, USA)
online coupled to an ACQUITY UPLC M-Class Peptide BEH
C18 column (130Å, 1.7μm, 75μm×250mm,Waters,Milford,
MA, USA). Peptides were separated at 48 °C with a flow rate of
300 nl/min, 4% solvent B from 0 to 11 min, followed by a
120min gradient to 50% solvent B. Solvent A consisted of water
+0.1% formic acid, while Solvent B was acetonitrile +0.1%
formic acid. The injected sample amount was 0.5 μg. Sample
ionization was achieved in the positive electrospray ionization
mode via a CaptiveSpray nanoBooster ionsource. The capillary
voltage was 1300 V, the nanoBooster pressure was 0.2 Bar,
drying gas was 150 °C, the flow rate was 3 l/min. External mass
calibration was done using the low concentration tuning mix
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from Agilent technologies via direct infusion. Internal mass cal-
ibration was performed via lock mass for each run using sodium
formate. The MS spectra were recorded with a fix cycle time
(2.5 s) over the mass range of m/z 150–2200 at 3 Hz with a
minimal precursor mass of m/z 322. The CID was performed
at 16 Hz for abundant precursors and at 4 Hz for ones of low
abundance. Singly charged peptides were excluded from analy-
sis, only multiple charged peptides were chosen for fragmenta-
tion. Collision energy for precursor signals was set automatically
followed by the manufacturer’s recommendations based on the
isolation m/z, isolation mass range width and ion charge state.
Active exclusion of 2 min. After 1 spectra was used except if the
intensity of the precursor was elevated threefold. For protein
analysis raw data were recalibrated using the Compass
DataAnalysis software 4.3 (Bruker Daltonics, Bremen,
Germany). Data were processed by the ProteinScape 3.0 soft-
ware (Bruker Daltonik GmbH, Bremen, Germany). Proteins
were identified by searching against the human Swissprot data-
base (2015_08) using the Mascot search engine version 2.5
(Matrix Science, London, UK) applying the following search
parameters: 7 ppm peptide mass tolerance, 0.05 Da fragment
mass tolerance, 2 missed cleavages, carbamidomethylation of
cysteines as fixed modification, deamidation (NQ) and oxidation
(M) as variable modifications and proteins were identified using
1% FDR limit. Label-free quantitation (LFQ) was then per-
formed using MaxQuant (software version 1.5.3.30), applying
default parameters. MaxQuant analysis searched only for pro-
teins identified previously by Mascot. Each LC-MS/MS run
was aligned using the “match between runs” feature (match time
window 0.8 min, alignment time window 15 min). The acquired
data underwent discriminant analysis and paired sample t-test
searching for proteins most characteristically describing tumor
and normal tissue. Bioinformatic analysis were performed by
IPA software (Ingenuity Databases, Mountain View, CA,
USA) to place identified proteins in known signalling pathways.
Results
1164 proteins were identified with at least 2 unique peptides
among the samples. Discriminant analysis revealed 18 proteins
describing either the tumor or normal tissue group. Paired sample
t-test were used to test for statistical significance between each
pair regarding thesemost descriptive 18 proteins (Table 1). The p
value was determined 0,1 considering the low number of sample
pairs of coherent tumor and normal tissue (n= 16). Thus, 8 pro-
teins showed significantly higher density in tumor including
tenascin (TNC), transmembrane emp24 domain-containing pro-
tein 2 (TMED2), dynein light chain 1, cytoplasmic (DYNLL1),
coactosin-like protein (COTL1), small proline-rich protein 2D
(SPRR2D), nucleolin (NCL), U5 small nuclear RNP 200-kDa
helicase (SNRNP200) and fatty aldehyde dehydrogenase
(ALDH3A2). Two proteins, desmoglein-1 (DSG1) and keratin
type I cytoskeletal 9 (KRT9) had significantly higher density in
the adjacent phenotipically normal tissue. Data and physiological
roles of identified proteins are demonstrated in Table 2.
Discussion
Despite rapid development of molecular diagnostics,
tumormarker discovery is still challenging. In the past few
years the interest of tumor research has gradually turned to
proteomics highlighting the observation that secreted proteins
are as important as tumor genetics. MS coupled with LC is
considered as the „gold standard” quantitative method in tu-
mor protein research. Due to the continuously evolving tech-
nical background, growing effort on investigation of HNSCC
proteome has also appeared. Initially, studies targeted in vitro
cell lines. Analysis of solid tumor tissues opened new ways in
tumormarker discovery, as these include the surrounding mi-
croenvironment also contributing to the malignant nature of
HNSCCs [5]. MS-based protein analysis had been previously
possible only on fresh frozen tissue samples with the
neccessity of organization steps including planned cryosection
and coordination of sample preparation. These drawbacks can
be overhelmed by FFPE tissues utilizing deparaffination pro-
cess [6]. Among existing papers reporting proteomic analysis
on FFPE samples, only a few reports address HNSCC [7].
Discovering possible tumor markers can be achieved by find-
ing proteins exclusively expressed by tumor tissue, but protein
abundance differences between normal and tumor tissue can
also be interpreted as a possible tumor marker. Our aim was to
explore protein abundance differences between phenotypical-
ly normal and tumor t issue on FFPE laryngeal-
hypopharyngeal tumor samples. To our knowledge no LC/
MS based proteomical studies exist exclusively investigating
LHSCC on FFPE samples.
We found eight and two proteins with significantly higher
and lower abundance in LHSCC, respectively, compared to
adjacent normal tissue (Table 2).
We foremost found TNC, DYNLL1, COTL1, SPRR2D,
SNRNP200, TMED2 and ALDH3A2 abundant in LHSCC
by LC/MS. Similar to our findings, one LC/MS study also
found NCL levels elevated in LHSCC [8].
We first found DSG1 down-regulated in LHSCC with LC/
MS, albeit rather isoform switch among desmogleins seems to
be determining in tumor invasivity.
We identified K1C9 down-regulated. One possible expla-
nation for down-regulation is the dedifferentiation. The other
probable hypothesis in our opinion is the lack of detectable
tryptic peptides of cytokeratins in peritumoral microenviron-
ment due to non-tryptic digestion during invasion.
IPA found no connection between proteins, but we uncov-
ered existing interactions being considered as possible targets
for future therapies in LHSCCs (Fig. 1).
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Table 2 Data of identified proteins
Gene
symbol
Accession Role HNSCC related literature
referral
IPA findings Mascot
score
MW
(kDa)*
∑ SC
(%)**
∑
Peptides***
TNC TENA_
HUM-
AN
ECM adhesion,
angiogenesis, EMT
overexpression as adverse
prognostic factor in oral
SCC (mRNA expression
analysis)
activating EGFR due to
EGF-like repeats
354 240.7 8.3 13
TMED2 TMED2_
HUM-
AN
trafficking between
endoplasmic
reticulum and Golgi
apparat, cytoskeletal
re-arrangement, cell
migration
up- and downregulation in
oral and
hypopharyngeal SCC
(miRNA expression and
gene expression
analysis, low sample
number, n = 5)
overexpression mediated by
NFE2L2 (a transcription
factor that may promote
carcinogenesis)
59.1 22.7 12.2 3
DYNLL1 DYL1_
HUM-
AN
intracellular
microtubular vesicle
transport,
maintenance of
cytoskeleton
up-regulation under
hypoxic conditions on
FaDuDD HNSCC cell
line (LC-MS/MS)
indirectly facilitating
HGF/c-MET pathway
82.3 8 21.6 5
COTL1 COTL1_
HUM-
AN
F-actin binding protein,
cellular motility
no reports found tumor associated protein in
chemical-induced SCC
model†
72.7 15.9 5.4 3
SPRR2D SPR2D_
HUM-
AN
function in skin barrier,
wound healing,
quenching of ROS,
terminal
differentiation
marker of stratified
squamous epithel
up-regulated in oral SCC
and NPC (RNA
analysis)
no data found 89.1 7.9 46.8 3
NCL NUCL_
HUM-
AN
co-factor in
transcription
regulation and RNA
transport
overexpressed in laryngeal
SCC (LC-MS/MS on
snap frozen tissue
samples)
recruiting EGFR mediated
signaling pathways,
facilitating EGFR
cytoplasmic tail
dimerization, direct
binding with SNRNP200
playing role in RNA
metabolism
316.2 76.6 17.9 11
SNRNP200 U520_
HUM-
AN
DeXH box protein,
pre-mRNA splicing
no reports found gene mutation in human
cutaneous SCC, direct
binding with NCL acting
as nuclear interacting
partner
51.5 244.4 1.3 2
ALDH3A2 AL3A2_
HUM-
AN
detoxification of
aldehydes
originating from
lipid peroxidation
processes
down-regulated in oral
SCC (16O/18O
proteomics analysis
using ESI-ion trap and
MALDI-TOF/TOF MS)
direct binding with EGFR‡ 64.6 54.8 7.9 3
DSG1 DSG1_
HUM-
AN
desmosome forming isoform switch among
DSGs in HNSCC (RNA
analysis)
indirectly down-regulated by
HGF in malignant mela-
noma
175 113.7 6.9 5
KRT9 K1C9_
HUM-
AN
intermediate filament of
intracytoplasmatic
cytoskeleton
down-regulated in
HNSCC lymph node
metastasis
(MALDI-Q-TOF
MS/MS); up-regulated
in NPC
(ESI-Q-TOF–MS)
no data found 1493.3 62 68.2 37
Boldface entries under “Gene symbol” indicate proteins significantly overexpressed in tumor comparing to the adjacent phenotipically normal tissue
(p < 0,1)
Italicized entries under “Gene symbol” indicate proteins with significantly lower abundance in tumor (p < 0,1) comparing to the adjaccent phenotipically
normal tissue
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Theoretically, inhibition of TMED2 or its inducer NFE2L2
may suggest a promising tool against HNSCC invasion. NCL
can act both as a recruiter and overexpressed protein of EGFR
mediated pathways and can facilitate dimerization of EGFR’s
cytoplasmic tail. Thus NCL overexpression can be both con-
sequence and initiator of EGFR activation. Therefore interfer-
ing NCL can also be promising in EGFR-positive HNSCCs,
while down-regulation may serve as a marker of anti-EGFR
therapy efficacy.
TNC containing EGF-like repeats may serve as targets
against EGFR-positive HNSCCs. Inhibiting EGFR results in
TNC down-regulation. Considering the diverse correlations
between TNC and EGFR, TNC can serve both a potential
target in HNSCC and therapeutic response marker in anti-
EGFR treatment.
DYNLL1-related cytoskeletal rearrangement and tumor
cell migration can be theoretically inhibited by anti-HGF ther-
apy, as DYNLL1 shows indirect interaction with HGF in
HGF/c-MET pathway in HNSCC.
IPA found indirect inhibition of DSG1 by HGF in malig-
nant melanoma highlighting that DSG1 down-regulation con-
tributes to cell-cell adhesion disruption easing invasion. Thus
inhibition of HGF can exert anti-tumor effect with
maintaining cell-to-cell junctions via stabilizing desmosomes
by DSG1 overexpression. Considering that EGFR pathway
shares common signals with HGF-mediated routes resulting
redundancy and frequently moderate therapeutic response to
anti-EGFR treatment, combined inhibition of EGFR and c-
MET/HGF pathway is emerging. Interfering redundant path-
ways (p44/p42 MAPK, PI3K/AKT, STAT) may have the de-
sired anti-cancer effect. Until routinely applied anticancer
drug combinations are available simultaneously targeting
HGF, EGF and NFE2L2 mediated pathways, inhibition of
overexpressed DYNLL, TNC, NCL and TMED2 may exert
anti-tumor effect on HNSCC beyond their diagnostic role.
IPA also found unclear interactions. COTL-1 is suggested
as tumor-associated protein upregulated on mouse carcino-
genesis model. SNRNP200 gene mutation was reported in
human cutaneous SCC. IPA found EGFR-ALDH3A2 direct
binding with unknown significance. NCL-SNRNP200 direct
binding demonstrates NCL’s place in RNA metabolism and
identifies SNRNP200 as a nuclear interacting partner.
Contrary to previous MS studies, abundance differences
were determined using label-free LC/MS based proteomics
exclusively on FFPE LHSCC samples. Feasibility of quanti-
tative LS/MS methods on FFPE samples had been
c-MET: hepatocyte growth factor receptor; EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; ECM: extracellular matrix; EMT:
endothelial-mesenchymal transition; HGF: hepatocyte growth factor;
HNSCC: head neck cancer squamous cell carcinoma; NFE2L2: nuclear factor, erythroid 2 like 2; NPC: nasopharyngeal carcinoma, ROS: reactive
oxygen species; SCC: squamous cell carcinoma
*molecular weight in kDa
**average sequence coverage in percentage
***the average number of peptides each protein was identified with
†without identified participating pathways
‡with unknown significance
CO: correlaon; PP: protein-protein binding; E: expression
Fig. 1 Note: This data is
mandatory. Please provide
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questionable for a long time due to cross-links and formalde-
hyde induced adducts [9]. Various extraction innovations
made protein recovery from FFPE samples as reliable and
diagnostically accurate as from fresh-frozen samples [10].
Labeling has several disadvantages compared to label-free
technique: protein loss due to each manipulation step,
neccessity of prerequisites (e.g. presence of cysteine-
containing peptides) and high costs. These disadvantages also
can be bypassed with label-free methods.
Our study also has limitations. Interestingly, IPA did not
detect SPRR2D and Krt9. This is probably due to the lack of
available IPA data. Continuous amplification of stored data
can reveal new interactions. The other drawback of our study
is the moderate sample number. It should be noted that our
primary aim was to design a pilot study for evaluation of
protein abundance differences between LHSCC and adjacent
healthy tissue.
Conclusion
Considering our initial favorable results, this study has clinical
relevance. Beside highlighting the proteomic difference be-
tween LHSCC and adjacent normal tissue, we found possible
LHSCCmarkers/targets that had not been in focus till date. On
the other hand, we proposed the potential in involving large
histopathological sample archives taking the reliability of
label-free LC/MS on FFPE samples into account facilitating
protein discovery. Nevertheless, this easy access to HNSCC
samples would make fresh frozen sectioning unneccessary
offering a cost-efficient and time-saving solution.
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